In Q1 2024, Abbott's FreeStyle Libre sales grew 25.5% to reach $1.5bn. The Plus version is gradually replacing the older FreeStyle Libre 2 sensor across many markets. England’s NHS, for example ...

Abbott recently launched a smartphone app that works with both its FreeStyle Libre 2 and FreeStyle Libre 3 CGM systems.

Linking the systems will allow clinicians to view glucose data captured by Libre glucose sensors within Epic’s systems.

If you use a continuous glucose monitoring (CGM) system, you usually have to remove the sensor before any imaging tests like X-rays, CT scans, and MRIs. But now, Abbott’s FreeStyle Libre 2 and 3 ...

Abbott has entered a first-of-its-kind agreement to integrate data from FreeStyle Libre CGM systems directly into Epic electronic health record systems in the United States, allowing clinicians to vie ...

Medtronic announced today that it submitted 510(k) applications to the FDA seeking clearance for an interoperable insulin ...

Abbott has launched the new Libre app in the U.S., making it easier than ever for users of both the FreeStyle Libre 2 and FreeStyle Libre 3 systems to track glucose readings and insights.

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

sensor-based CGM system — FreeStyle Libre. However, currency fluctuations may restrict Abbott’s growth potential. In the past year, this Zacks Rank #2 (Buy) company’s shares have risen 19.6% ...

The stock carries a Zacks Rank #2 (Buy) currently. Within Abbott’s Established ... sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.